.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The HIPARCO randomized clinical trial investigated whether treating obstructive sleep apnea with CPAP could improve blood-pressure control in patients with resistant hypertension. Adults receiving multiple antihypertensive medications were randomized to CPAP or no CPAP while continuing their usual cardiovascular therapy. After 12 weeks, CPAP was associated with a greater reduction in 24-hour mean blood pressure and diastolic blood pressure, along with improvement in the normal nocturnal blood-pressure dipping pattern. The degree of benefit was related to CPAP use, emphasizing adherence as an important determinant of effect. The study did not establish that CPAP eliminates the need for antihypertensive medication or that every patient with OSA will achieve a major blood-pressure reduction. Instead, it provides evidence that treating OSA can contribute to cardiovascular risk management, particularly in resistant hypertension. This directly matches NAPCON's sleep-medicine session on screening triggers beyond snoring, including resistant hypertension and diabetes. For pulmonologists and sleep physicians, the paper supports asking about OSA when hypertension is difficult to control and discussing CPAP as part of a broader multidisciplinary management strategy.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The HIPARCO randomized clinical trial investigated whether treating obstructive sleep apnea with CPAP could improve blood-pressure control in patients with resistant hypertension. Adults receiving multiple antihypertensive medications were randomized to CPAP or no CPAP while continuing their usual cardiovascular therapy. After 12 weeks, CPAP was associated with a greater reduction in 24-hour mean blood pressure and diastolic blood pressure, along with improvement in the normal nocturnal blood-pressure dipping pattern. The degree of benefit was related to CPAP use, emphasizing adherence as an important determinant of effect. The study did not establish that CPAP eliminates the need for antihypertensive medication or that every patient with OSA will achieve a major blood-pressure reduction. Instead, it provides evidence that treating OSA can contribute to cardiovascular risk management, particularly in resistant hypertension. This directly matches NAPCON's sleep-medicine session on screening triggers beyond snoring, including resistant hypertension and diabetes. For pulmonologists and sleep physicians, the paper supports asking about OSA when hypertension is difficult to control and discussing CPAP as part of a broader multidisciplinary management strategy.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
